Merck has signed a landmark voluntary licensing deal with the UN-backed Medicines Patent Pool to expand low-cost access to its Covid-19 antiviral pill throughout the developing world.
It is one of the first royalty-free licensing agreements struck by a pharmaceutical company for a key Covid-19 medical technology and should boost generic manufacturing of Merck’s drug molnupiravir if it is authorised by regulators, according to experts.
Merck has already struck licensing deals with several Indian manufacturers as it races to meet surging global demand for the treatment, which has not yet secured regulatory approval.
您已閱讀18%（619字），剩余82%（2755字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。